Pharmacopsychiatry 2013; 46(04): 137-146
DOI: 10.1055/s-0032-1331749
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Parental Perceived Benefits of OROS-Methylphenidate Treatment for the Child with Attention-Deficit/Hyperactivity Disorder and for Parents Themselves

J.-W. Kim
1  Department of Child and Adolescent Psychiatry, Seoul National University Hospital, Seoul, Korea
7  These authors contributed equally to this work
,
S. Park
1  Department of Child and Adolescent Psychiatry, Seoul National University Hospital, Seoul, Korea
7  These authors contributed equally to this work
,
B.-N. Kim
1  Department of Child and Adolescent Psychiatry, Seoul National University Hospital, Seoul, Korea
,
M.-S. Shin
1  Department of Child and Adolescent Psychiatry, Seoul National University Hospital, Seoul, Korea
,
S.-C. Cho
1  Department of Child and Adolescent Psychiatry, Seoul National University Hospital, Seoul, Korea
,
J.-H. Kim
2  Department of Psychiatry, Pusan National University Hospital. Pusan, Korea
,
J.-W. Son
3  Department of Psychiatry, Chungbuk National University Hospital. Cheongju, Korea
,
Y.-M. Shin
4  Department of Psychiatry, Ajou University Hospital. Suwon, Korea
,
U.-S. Chung
5  Department of Psychiatry, Kyungpook National University Hospital. Daegu, Korea
,
D.-H. Han
6  Department of Psychiatry, Chung Ang University Hospital. Seoul, Korea
› Author Affiliations
Further Information

Publication History

received 11 August 2012
revised 12 November 2012

accepted 27 November 2012

Publication Date:
30 January 2013 (online)

Abstract

Introduction:

Given the shortage of studies on parental perceived benefits of OROS-methylphenidate treatment in Asian populations, we assessed parental response to OROS-methylphenidate treatment of Korean children with attention-deficit/hyperactivity disorder (ADHD), in relation to children’s academic performance and behavioral symptoms as well as parental rearing stress and depressive symptoms.

Methods:

We enrolled 132 medication-naïve children with ADHD into a multicenter, open-label, 12-week trial of OROS-MPH. The outcome measures were the ADHD rating scale-IV (ADHD-RS), the comprehensive attention test and academic performance rating scale, and the clinical global impression (CGI)-severity/improvement instrument (for the children) and Beck depression inventory and parenting stress index (for their parents).

Results:

We found parent-perceived improvements in children’s ADHD-related behavioral symptoms and academic function and their parents' depressive symptoms and parenting stress. Investigator-rated ADHD symptoms and subjects' neuropsychological function were also improved (p<0.001).

Discussion:

Parents of Korean children with ADHD perceive that OROS-methylphenidate treatment improves their children’s academic function and behavior as well as their own child-rearing stress and emotional state. These findings must be interpreted with caution, due to a non-comparative open-label trial.